Floatz logo

IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER

CNS Malignancies

Eli Lilly and Companymonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the CNS Malignancies cohort.

Asset / SponsorPhaseRating
CARMUSTINE
SWOG Cancer Research Network
Phase 3B
o6-benzylguanine
SWOG Cancer Research Network
Phase 3B
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC
TZ-3321
Washington University School of Medicine
Phase 2CCC

View all 13 →

Same molecule, other indications

IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER is also rated in:

urothelial carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
lung cancerDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →